Cirsium Biosciences Showcases 50,000-Square-Foot Plant-Based AAV Facility and Partner-Backed Buildout

Cirsium Biosciences, a specialist in plant-based adeno-associated virus manufacturing, spent the week highlighting the buildout and early showcasing of its new 50,000-square-foot viral vector facility. The company emphasized that the highly automated site is designed around a full seed-to-viral-vector lifecycle and is coming online as a commercial-scale platform.

Recent LinkedIn posts detailed a “First Look” walkthrough for external visitors, who reportedly viewed the operation as larger and more technically advanced than expected. Cirsium positioned the event as a way to demonstrate its vertically integrated production flow, advanced automation, and potential to accelerate the delivery of gene and cell therapies.

In parallel, Cirsium outlined the ecosystem of partners behind the facility, including ARPA-H as a government funding contractor supporting its reimagined AAV manufacturing technology. Vital Ventures Consulting is contributing to plant molecular farming process and facility design, while EverGlade oversees project management and Artechno Growsystems provides automated vertical farming systems.

These collaborations underscore that the 50,000-square-foot site is a capital- and coordination-intensive undertaking intended to deliver scalable, continuous plant-based AAV production. If the technology performs as described, the platform could lower vector manufacturing costs, enhance supply reliability, and increase Cirsium’s appeal as a strategic supplier to gene therapy developers.

However, the company’s communications did not disclose project timelines, total capital investment, regulatory status, or signed customer contracts, leaving revenue visibility and commercialization pacing uncertain. Overall, the week marked a significant step in showcasing Cirsium’s infrastructure buildout and signaling its ambition to become a differentiated player in the constrained viral vector supply chain.